The basics:

Novo will use Anthropic Claude AI models in R&D workflows
Partnership will support drug discovery, biological research
Anthropic technology will also support AI-driven software development
Deal follows Novo’s AI partnerships with OpenAI, AWS

Novo is adding Anthropic to its growing list of technology partners as the pharma giant looks to use artificial intelligence to speed up drug research and development.

The company announced the partnership Sept. 16. Novo will initially tap Anthropic’s Claude AI models for specific R&D workflows. Financial terms were not disclosed.

The collaborators said that work will include using the technology to help scientists address drug discovery challenges, analyze biological questions and identify areas where AI could have the greatest impact.

The relationship also includes using Anthropic’s technology to support AI-driven software development at Novo, the partners said.

According to Novo, the collaboration will include data-governance measures and human oversight.

All in on AI

The relationship with Anthropic is the latest in a series of AI initiatives at Novo.

In April, the company unveiled a partnership with OpenAI. As part of that arrangement, Novo said it will use OpenAI’s capabilities to analyze complex datasets, identify promising drug candidates and reduce the time from research to patient.

Last month, Novo announced a partnership with Amazon Web Services. The company will use AWS on AI projects involving drug discovery and the analysis of genomic, imaging and clinical data.

As a leading global healthcare company, Novo employs about 66,700 people in 80 countries. Its key medicines include GLP-1 drugs Ozempic for type 2 diabetes and Wegovy for weight management. Headquartered in Denmark, Novo has its U.S. base in Plainsboro.

It joins other pharmaceutical companies, such as Sanofi, Genmab and AbbVie, in using Anthropic’s Claude platform for research, development and other operations.

Other technology companies are partnering with drugmakers across the industry, including NVIDIA, Microsoft and Google. Those collaborations focus on applying AI to areas like identifying drug candidates, analyzing biological data and streamlining the development process.

Supercharging R&D

Novo CEO and President Mike Doustdar said the Anthropic partnership “is another testament to our ambition to become the world’s most AI-driven healthcare company.”

“Joining forces with Anthropic will supercharge our R&D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,” he said.

Joining forces with Anthropic will supercharge our R&D organization and help us on our mission to bring new, transformative health solutions to people living with chronic diseases.
– Mike Doustdar, CEO and president, Novo

“AI can help us increase productivity in R&D and compress the path from research to marketed product. But beyond this, AI tools can also offer completely new scientific opportunities and aid reasoning and understanding of human biology and drug mechanics,” the CEO added.

Anthropic co-founder and CEO Dario Amodei remarked, “AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade.”

He said, “By giving leading researchers access to safe, capable, and trusted frontier models, we can shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life. That is exactly what our collaboration with Novo is built to achieve.”

The partnership comes days after Novo revealed a rebrand. Along with an updated version of its Apis bull logo and new slogan, “Lasting Health Starts Now,” the company shortened its name from Novo Nordisk to Novo.